Hints and tips:
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Last year, Takeda acquired US oncology group Ariad Pharmaceuticals for $5.2bn and it later tried to acquire Valeant, the Canadian drugmaker, for around $10bn. but the talks collapsed over price....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...worth more than $5bn, according to figures prepared by Dealogic for the Financial Times — Thermo Fisher’s $7.2bn deal for drug ingredients maker Patheon, and Takeda’s $5.4bn takeover of cancer specialist Ariad...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...The Japanese company, which is on the hunt for acquisitions in the US, announced plans on Monday to buy Ariad Pharmaceuticals, a US firm making drugs to treat rare cancers, in a $5.2 billion tie-up....
...In Tokyo Takeda Pharmaceuticals, which has been looking to expand its presence in the US and this week bought US-listed oncology group Ariad Pharmaceuticals for $5.2bn, fell 2.6 per cent....
...Shares of Bluebird Bio rose 12 per cent to $112.23, ARIAD Pharmaceuticals climbed 2 per cent to $8.25 and Regeneron Pharmaceuticals advanced 4 per cent to $428.95....
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Just one of hundreds of raids carried out worldwide through Interpol’s Operation Pangea V, nearly 200 police and regulatory agencies combined efforts to clamp down on the complex multimillion dollar international...
...Research by its parent company Procter & Gamble’s Fairy Liquid and Ariel teams enabled Clairol to devise a product that started as a foam – easier to handle than the usual dye – but once on the hair collapsed...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Mr Paracuelles said he expected Japan to stage a V-shaped recovery in the second half of the year which would buoy Singapore’s economy....
...Examples include Astellas Pharma of Japan’s $3.8bn acquisition of OSI Pharmaceuticals in the US, and Korea National Oil’s $2.8bn deal with Britain’s Dana Petroleum....
...Small cap Ariad Pharmaceuticals rose 9.1 per cent to $2.77 after AP24534, its leukaemia drug, received “orphan” status from the Food and Drug Administration....
International Edition